--- the subscriber area has no ads and those above are not selected or endorsed by this site ---


Resonant shipments & 3Q19 schedule plus EMAN & AUO ?3


Resonant has scheduled its third quarter report for the evening of November 5th.  The average of estimates from 5 analysts comes to a loss of 20 cents from revenue of $334K, increasing to $620K this quarter.  However, in its press release, management chose instead to highlight royalty unit shipments in the third quarter have exceeded those for the first half, and that royalty revenue increased sequentially. 

I don't see that as a big accomplishment, since second quarter revenue was a disappointing $63K.  RESN hasn't traded in the pre-market, and there is potential for a sling-shot effect from depressed valuation.  However, I think that waiting for year-end tax-loss selling has at least as good a chance of getting the best priced entry point.  Those who feel they have insufficient current positions and are prone to fear of missing out, might consider splitting any accumulation.

It can be even harder to  keep the long-term prospects in mind when it comes to GRoDT stocks, but that's what informed my decision to liquidate AUO when I did.  It has now delisted its shares from NYSE and only trades OTC in America.  Expect that section to move to the public side of the website before year-end.  The same eventual fate probably awaits EMAN, which has scheduled its third quarter report for the morning of November 7th.  Only two analysts still cover the company and they expect the company to lose a penny or two per share from about $7M in sales, with no guesses on how those will proceed.  As predicted long ago, eMagin has implemented cost-cutting measures and is preparing for a reverse split.  Don't expect to hear more from me about them unless there is some surprise.